Immunogenicity and Safety of a Fully Liquid DTaP-IPV-Hep B-PRP-T Vaccine at 2-4-6 Months of Age in Peru

Abstract

Objectives: To assess the immunogenicity and safety of a new candidate, fully liquid, hexavalent DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim, an AcXim family vaccine) compared to a licensed hexavalent DTaP-IPV-Hep B// PRP-T vaccine (Infanrix hexa ) in Peru.